Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19

Humanized Virus Suppressing Factor-variant 13 (hzVSF-v13), a monoclonal IgG4 antibody against vimentin, was investigated in moderate to severe COVID-19 pneumonia through a Phase II study. Patients were randomized to two different IV doses of the test drug or saline with standard of care. Overall, 64...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasenohadi, Prasenohadi, Burhan, Erlina, Dhunny, Sri, Suharno, Wahyuningsih, Wabnitz, Paul, Kim, Yoon-Won, Petrosillo, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181020/
https://www.ncbi.nlm.nih.gov/pubmed/35683351
http://dx.doi.org/10.3390/jcm11112961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181020/
https://www.ncbi.nlm.nih.gov/pubmed/35683351
http://dx.doi.org/10.3390/jcm11112961

Ejemplares similares